keyword
MENU ▼
Read by QxMD icon Read
search

Glp-1r

keyword
https://www.readbyqxmd.com/read/29444223/glp-1-receptor-expression-within-the-human-heart
#1
Laurie L Baggio, Bernardo Yusta, Erin E Mulvihill, Xiemin Cao, Catherine J Streutker, Jagdish Butany, Thomas P Cappola, Kenneth B Margulies, Daniel J Drucker
Glucagon-like peptide-1 receptor (GLP-1R) agonists, used to treat type 2 diabetes and obesity, reduce rates of myocardial infarction and cardiovascular death. The GLP-1R has been localized to the human sinoatrial node; however, its expression in ventricular tissue remains uncertain. Here we studied GLP-1R expression in the human heart using GLP-1R-directed antisera, quantitative PCR, reverse transcription PCR to detect full length mRNA transcripts, and in situ hybridization. GLP1R mRNA transcripts, encompassing the entire open reading frame, were detected in all four cardiac chambers from 15 hearts at levels approximating those detected in human pancreas...
February 12, 2018: Endocrinology
https://www.readbyqxmd.com/read/29439603/semaglutide-in-type-2-diabetes-is-it-the-best-glucagon-like-peptide-1-receptor-agonist-glp-1r-agonist
#2
Sheila A Doggrell
Glucagon-like peptide-1 (GLP-1) is produced by the gut, and in a glucose-dependent manner stimulates insulin secretion while inhibiting glucagon secretion, reduces appetite and energy intake, and delays gastric emptying. The GLP-1R agonist semaglutide has recently been registered for use in the treatment of type 2 diabetes. Area covered: This review is of semaglutide in type 2 diabetes, and considers which properties of this GLP-1R agonist, may be responsible for its clinical outcome benefits in this condition...
February 13, 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29434185/glucagon-like-peptide-1-receptor-regulates-endoplasmic-reticulum-stress-induced-apoptosis-and-the-associated-inflammatory-response-in-chondrocytes-and-the-progression-of-osteoarthritis-in-rat
#3
Jian Chen, Jun-Jun Xie, Ke-Si Shi, Yun-Tao Gu, Cong-Cong Wu, Jun Xuan, Yue Ren, Long Chen, Yao-Sen Wu, Xiao-Lei Zhang, Jian Xiao, De-Zhong Wang, Xiang-Yang Wang
Treatments for osteoarthritis (OA) are designed to restore chondrocyte function and inhibit cell apoptosis. Previous studies have shown that activation of the glucagon-like peptide-1 receptor (GLP-1R) leads to anti-inflammatory and anti-apoptotic effects. However, the role of GLP-1R in the pathological process of OA is unclear. In present work, we aimed to demonstrate the potential effect of GLP-1R on chondrocytes and elucidate its underlying mechanisms. We found that activation of GLP-1R with liraglutide could protect chondrocytes against endoplasmic reticulum stress and apoptosis induced by interleukin (IL)-1β or triglycerides (TGs)...
February 12, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29433086/potential-roles-for-glucagon-like-peptide-1-7-36-amide-and-cholecystokinin-in-anorectic-response-to-the-trichothecene-mycotoxin-t-2-toxin
#4
Wenda Wu, Kun Sheng, Xinglian Xu, Haibin Zhang, Guanghong Zhou
Anorexia is a hallmark of animal and human exposed to T-2 toxin, a most poisonous trichothecene mycotoxins contaminating various cereal grains including wheat, corn and barley. Although this adverse effect has been well characterized in several animal species, the underlying mechanisms are unclear. The goal for this study was to elucidate the roles of two gut satiety hormones, glucagon-like peptide-17-36amide (GLP-1) and cholecystokinin (CCK) in T-2 toxin-evoked anorectic response using a mouse anorexia bioassay...
February 9, 2018: Ecotoxicology and Environmental Safety
https://www.readbyqxmd.com/read/29432213/regulation-of-intestinal-lipid-and-lipoprotein-metabolism-by-the-proglucagon-derived-peptides-glucagon-like-peptide-1-and-glucagon-like-peptide-2
#5
Erin E Mulvihill
PURPOSE OF REVIEW: The intestine is highly efficient at absorbing and packaging dietary lipids onto the structural protein apoB48 for distribution throughout the body. Here, we summarize recent advances into understanding the physiological and pharmacological actions of the proglucagon-derived peptides: glucagon like peptide 1 (GLP-1) and glucagon like peptide 2 (GLP-2) on intestinal lipoprotein secretion. RECENT FINDINGS: Several recent studies have elucidated mechanisms underlying the paradoxical effects of GLP-1 and GLP-2 on intestinal production of triglyceride-rich lipoproteins (TRLs)...
February 9, 2018: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/29423016/exendin-4-promotes-the-osteogenic-differentiation-of-osteoblasts-via-the-hedgehog-gli1-signaling-pathway
#6
Liu Gao, Shilun Li, Yukun Li
This study aimed to investigate the effect and mechanisms of Exendin-4 mediated-Hedgehog/Gli1 signaling pathway on the differentiation of osteoblasts in mouse. The alkaline phosphate activity, alizarin red staining and expression of Gli1, GLP-1R, Hedgehog, Runx2 and osteocalcin were analyzed using PCR and Western blot analysis after treating the osteoblastic cell line MC3T3-E1 with Exendin-4. Osteoblasts were treated with Gli1-siRNA and Hedgehog receptor antagonist Cyclopamine (Cy) and analyzed for their impact on the Hedgehog/Gli1 signaling pathway...
2018: American Journal of Translational Research
https://www.readbyqxmd.com/read/29412838/glucagon-like-peptide-1-receptor-mediated-control-of-cardiac-energy-metabolism
#7
Rami Al Batran, Malak Almutairi, John R Ussher
Glucagon-like peptide-1 receptor (GLP-1R) agonists are frequently used to improve glycemia in patients with type 2 diabetes (T2D). Recent data from cardiovascular outcomes trials for the GLP-1R agonists, liraglutide and semaglutide, have also demonstrated significant reductions in death rates from cardiovascular causes in patients with T2D. As cardiovascular death is the number one cause of death in patients with T2D, understanding the mechanisms by which GLP-1R agonists such as liraglutide and semaglutide improve cardiac function is essential...
February 2018: Peptides
https://www.readbyqxmd.com/read/29412835/control-of-insulin-secretion-by-glp-1
#8
Ben Jones, Stephen R Bloom, Teresa Buenaventura, Alejandra Tomas, Guy A Rutter
Stimulation of insulin secretion by glucagon-like peptide-1 (GLP-1) and other gut-derived peptides is central to the incretin response to ingesting nutriments. Analogues of GLP-1, and inhibitors of its breakdown, have found widespread clinical use for the treatment of type 2 diabetes (T2D) and obesity. The release of these peptides underlies the improvements in glycaemic control and disease remission after bariatric surgery. Given therapeutically, GLP-1 analogues can lead to side effects including nausea, which limit dosage...
February 2018: Peptides
https://www.readbyqxmd.com/read/29412813/insulin-and-igf-1-receptor-autocrine-loops-are-not-required-for-exendin-4-induced-changes-to-pancreatic-%C3%AE-cell-bioenergetic-parameters-and-metabolism-in-brin-bd11-cells
#9
Jordan Rowlands, Vinicius Cruzat, Rodrigo Carlessi, Philip Newsholme
Pharmacological long lasting Glucagon-like peptide-1 (GLP-1) analogues, such as Exendin-4, have become widely used diabetes therapies. Chronic GLP-1R stimulation has been linked to β-cell protection and these pro-survival actions of GLP-1 are dependent on the activation of the mammalian target of rapamycin (mTOR) leading to accumulation of Hypoxia inducible factor 1 alpha (HIF-1α). Recent studies from our lab indicate that prolonged GLP-1R stimulation promotes metabolic reprograming of β-cells towards a highly glycolytic phenotype and activation of the mTOR/HIF-1α pathway was required for this action...
February 2018: Peptides
https://www.readbyqxmd.com/read/29411931/neuroprotective-mechanisms-of-glucagon-like-peptide-1-based-therapies-in-ischaemic-stroke-a-systematic-review-based-on-pre-clinical-studies
#10
Ida R Marlet, Joakim N E Ölmestig, Tina Vilsbøll, Jørgen Rungby, Christina Kruuse
Glucagon-like peptide-1 (GLP-1)-based therapies, GLP-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4Is) are widely used for the treatment of type 2 diabetes. Increasing evidence suggests that they may provide neuroprotection. The aim of this MiniReview was to systematically evaluate the proposed mechanism of action for GLP-1-based therapies in ischaemic brain damage in animals. We performed a literature search using Medline, Embase and The Cochrane Library. GLP-1-based therapies administered before, during or after experimental stroke in diabetic and non-diabetic animals were evaluated...
February 7, 2018: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29406832/coagonist-of-glp-1-and-glucagon-receptors-ameliorates-non-alcoholic-fatty-liver-disease
#11
Vishal J Patel, Amit Arvind Joharapurkar, Samadhan Kshirsagar, Maulik S Patel, Brijesh K Sutariya, Hiren M Patel, Dheerendra Pandey, Dipam Patel, Ramchandra Ranvir, Shekhar Kadam, Rajesh Bahekar, Mukul Jain
Nonalcoholic fatty liver disease (NAFLD) is often associated with obesity and type 2 diabetes. Coagonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) are under clinical investigation for the treatment of obesity and type 2 diabetes. In this study, we have demonstrated the effect of a balanced coagonist in the treatment of NAFLD using mice models. GLP-1R agonist exendin-4, glucagon, and coagonist (Aib2 C24 Chimera2) were administered to C57BL6/J mice, in which NAFLD was induced by carbon tetrachloride (CCl4) treatment after in high fat diet (HFD) feeding, and CDAHFD (choline-deficient, L-amino acid-defined, HFD)...
February 6, 2018: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/29404215/equine-glucagon-like-peptide-1-receptor-physiology
#12
Murad H Kheder, Simon R Bailey, Kevin J Dudley, Martin N Sillence, Melody A de Laat
Background: Equine metabolic syndrome (EMS) is associated with insulin dysregulation, which often manifests as post-prandial hyperinsulinemia. Circulating concentrations of the incretin hormone, glucagon-like peptide-1 (GLP-1) correlate with an increased insulin response to carbohydrate intake in animals with EMS. However, little is known about the equine GLP-1 receptor (eGLP-1R), or whether GLP-1 concentrations can be manipulated. The objectives were to determine (1) the tissue localisation of the eGLP-1R, (2) the GLP-1 secretory capacity of equine intestine in response to glucose and (3) whether GLP-1 stimulated insulin secretion from isolated pancreatic islets can be attenuated...
2018: PeerJ
https://www.readbyqxmd.com/read/29397375/once-weekly-glp-1r-agonists-moving-the-goal-posts
#13
Abd A Tahrani, Srikanth Bellary, Anthony H Barnett
No abstract text is available yet for this article.
January 31, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29397068/a-mechanism-for-agonist-activation-of-the-glucagon-like-peptide-1-glp-1-receptor-through-modelling-molecular-dynamics
#14
Carla Gómez Santiago, Emanuele Paci, Dan Donnelly
The receptor for glucagon-like peptide 1 (GLP-1R) is a validated drug target for the treatment of type 2 diabetes and obesity. Recently the first three structures of GLP-1R were published - an X-ray structure of the apo transmembrane domain in the inactive conformation; an X-ray structure of the full-length receptor bound to a truncated peptide agonist; and a cryo-EM structure of the full-length receptor bound with GLP-1 and coupled to the G protein Gs. Since the inactive structure was incomplete, and the two active-state structures shared significant differences, we utilised all available knowledge to build hybrid models of the full length active and inactive state receptors...
January 31, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29357809/coagonist-of-glp-1-and-glucagon-receptor-ameliorates-development-of-non-alcoholic-fatty-liver-disease
#15
Vishal Patel, Amit Joharapurkar, Samadhan Kshirsagar, Brijesh Sutariya, Maulik Patel, Hiren Patel, Dheerendra Pandey, Dipam Patel, Ramchandra Ranvir, Shekhar Kadam, Rajesh Bahekar, Mukul Jain
Background-Obesity, diabetes and dyslipidemic are the key pathogenic stimulus that enhances progression of non-alcoholic fatty liver disease (NAFLD). Coagonist of glucagon like-peptide-1 (GLP-1) receptor (GLP-1R) and glucagon receptor (GCGR) are being evaluated for obesity and diabetes. GLP-1 analogues have shown to reverse diabetes and obesity. Glucagon treatment reduces lipids after acute and chronic treatment. Objective-In this study, we have investigated the effect of coagonist on prevention of NAFLD induced by long-term feeding of high fat diet (HFD)...
January 18, 2018: Cardiovascular & Hematological Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29356866/retrofitting-baculoviral-vector-with-sleeping-beauty-transposon-system-competent-for-long-term-reporter-gene-imaging-in-vivo
#16
Yu Pan, Jing Lv, Donghui Pan, Min Yang, Huijun Ju, Jinxin Zhou, Liying Zhu, Yifan Zhang
Reporter gene imaging is widely used for non-invasively detecting tumorigenesis, trafficking therapeutic cells, and monitoring treatment effect. Baculoviral vectors (BVs) have been utilized as transgenic vectors in the reporter gene imaging systems in recent years. However, BV-mediated report gene imaging can only provide short-term investigation due to its transient transgene expression, which is incompetent for the long-term applications. In the current study, we reconstructed a series of hybrid BVs with several elements, to investigate the feasibility of this hybrid BV-mediated long-term reporter gene imaging in vivo...
January 22, 2018: Applied Microbiology and Biotechnology
https://www.readbyqxmd.com/read/29355505/glutazumab-a-novel-long-lasting-glp-1-anti-glp-1r-antibody-fusion-protein-exerts-anti-diabetic-effects-through-targeting-dual-receptor-binding-sites
#17
Caina Li, Miaomiao Yang, Xiaofeng Wang, Hua Zhang, Chenjiang Yao, Sujuan Sun, Quan Liu, Hao Pan, Shuainan Liu, Yi Huan, Shengnan Li, Jun Cao, Xing Wang, Yong Guo, Nan Guo, Shuqian Jing, Cheng Zhang, Zhufang Shen
AIMS: Glucagon like-peptide-1 (GLP-1)-based drugs have been proposed as mono- or combined therapy for type 2 diabetes mellitus. Thus we characterized a novel antibody fusion protein engineered by linking the human GLP-1 derivative to a humanized GLP-1 receptor (GLP-1R) antibody via a peptide linker. MATERIALS AND METHODS: Glutazumab was characterized by receptor binding and reporter activation assays, and its specificity was investigated with the aid of the cognate receptor antagonist exendin (9-39) and antibody Ab1...
January 17, 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29335487/increased-expression-of-glp-1r-in-proliferating-islets-of-men1-mice-is-detectable-by-68ga-ga-do3a-vs-cys40-exendin-4-pet
#18
Azita Monazzam, Joey Lau, Irina Velikyan, Su-Chen Li, Masoud Razmara, Ulrika Rosenström, Olof Eriksson, Britt Skogseid
Multiple endocrine neoplasia type 1 (MEN1) is an endocrine tumor syndrome caused by heterozygous mutations in the MEN1 tumor suppressor gene. The MEN1 pancreas of the adolescent gene carrier frequently contain diffusely spread pre-neoplasias and microadenomas, progressing to macroscopic and potentially malignant pancreatic neuroendocrine tumors (P-NET), which represents the major death cause in MEN1. The unveiling of the molecular mechanism of P-NET which is not currently understood fully to allow the optimization of diagnostics and treatment...
January 15, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29331643/glucagon-like-peptide-1-signaling-inhibits-allergen-induced-lung-il-33-release-and-reduces-group-2-innate-lymphoid-cell-ilc2-cytokine-production-in-vivo
#19
Shinji Toki, Kasia Goleniewska, Sara Reiss, Jian Zhang, Melissa H Bloodworth, Matthew T Stier, Weisong Zhou, Dawn C Newcomb, Lorraine B Ware, Gregg D Stanwood, Aurelio Galli, Kelli L Boyd, Kevin D Niswender, R Stokes Peebles
BACKGROUND: IL-33 is one of the most consistently associated gene candidates for asthma identified by GWAS. Studies in mice and in human cells have confirmed the importance of IL-33 in inducing type-2 cytokine production from both group 2 innate lymphoid cells (ILC2) and Th2 cells. However, there are no pharmacologic agents known to inhibit IL-33 release from airway cells. OBJECTIVE: To determine the effect of glucagon like peptide receptor-1 GLP-1R signaling on aeroallergen-induced airway IL-33 production and release and on innate type-2 airway inflammation...
January 10, 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29329976/therapeutic-potential-of-spinal-glp-1-receptor-signaling
#20
REVIEW
Dongao Zhang, Gang Lv
GLP-1 signaling pathway has been well studied for its role in regulating glucose homeostasis, as well as its beneficial effects in energy and nutrient metabolism. A number of drugs based on GLP-1 have been used to treat type 2 diabetes mellitus. GLP-1R is expressed in multiple organs and numerous experimental studies have demonstrated that GLP-1 signaling pathway exhibits pro-survival functions in various disorders. In the central nervous system, stimulation of GLP-1R produces neuroprotective effects in specific neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease...
January 9, 2018: Peptides
keyword
keyword
13153
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"